Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1986 2
1989 1
1990 1
1991 1
1992 3
1993 6
1994 5
1995 6
1996 3
1997 3
1998 10
1999 13
2000 11
2001 11
2002 33
2003 23
2004 28
2005 36
2006 33
2007 29
2008 33
2009 25
2010 30
2011 35
2012 30
2013 29
2014 19
2015 12
2016 22
2017 21
2018 17
2019 5
2020 6
2021 6
2022 6
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 10782805

505 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Maini RN, et al. Arthritis Rheum. 1998 Sep;41(9):1552-63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. Arthritis Rheum. 1998. PMID: 9751087 Clinical Trial.
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. Ruperto N, et al. Arthritis Rheum. 2007 Sep;56(9):3096-106. doi: 10.1002/art.22838. Arthritis Rheum. 2007. PMID: 17763439 Free article. Clinical Trial.
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P, Bouman-Thio E. Westhovens R, et al. J Rheumatol. 2006 May;33(5):847-53. Epub 2006 Apr 1. J Rheumatol. 2006. PMID: 16583466 Clinical Trial.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group. Cohen SB, et al. Arthritis Rheum. 2006 Sep;54(9):2793-806. doi: 10.1002/art.22025. Arthritis Rheum. 2006. PMID: 16947627 Free article. Clinical Trial.
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Quinn MA, et al. Arthritis Rheum. 2005 Jan;52(1):27-35. doi: 10.1002/art.20712. Arthritis Rheum. 2005. PMID: 15641102 Free article. Clinical Trial.
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF; PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial. Shergy WJ, et al. J Rheumatol. 2002 Apr;29(4):667-77. J Rheumatol. 2002. PMID: 11950005 Clinical Trial.
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM; DANCER Study Group. Emery P, et al. Arthritis Rheum. 2006 May;54(5):1390-400. doi: 10.1002/art.21778. Arthritis Rheum. 2006. PMID: 16649186 Free article. Clinical Trial.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W; ACTION Study Group. Genovese MC, et al. Arthritis Rheum. 2008 Sep;58(9):2652-61. doi: 10.1002/art.23732. Arthritis Rheum. 2008. PMID: 18759293 Free article. Clinical Trial.
505 results